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1. Introduction 
1.1 Epidemiology 
In the last 80 years, the incidence of gastric cancer and gastric cancer-related mortality has 
decreased significantly. However, gastric cancer is the 4th most common  cancer and the 2nd 
common cause of cancer associated mortality in the world (Crew, K.D. Neugut, A.I., 2006, 
Ferlay, J., et al., 2010, Ferlay, J., et al., 2010, Jemal, A., et al., 2010, Krejs, G.J., 2010, Malvezzi, 
M., et al., 2010, Sasako, M., et al., 2010, Shin, H.R., et al., 2010). Gastric cancer according to 
anatomic location in the stomach, proximal (cardia) and distal (noncardia) is divided into 2 
groups. Although decreasing, distal located tumors are still the most common type in 
developing countries. While there is an increase in proximal located tumors, the distal 
located gastric cancers have been decreasing in western societies (Ferlay, J., et al., 2010, 
Krejs, G.J., 2010, Malvezzi, M., et al., 2010). More than 90% of gastric cancers are 
adenocarcinomas and can be either intestinal, or diffuse type (Crew, K.D. Neugut, A.I., 2006, 
Krejs, G.J., 2010).  
The incidence vary significantly throughout the world. More than half of all gastric cancers 
in the world are seen in eastern Asia (Sasako, M., et al., 2010).  Korea and Japan had the 
highest incidence countries. While its incidence is 60/100.000 for men and 25/100.000 for 
women in Korea and Japan (Long, N., et al., 2010),  it is around 5/100.000 for Australia and 
New Zealand (Crew, K.D. Neugut, A.I., 2006, Ferlay, J., et al., 2010, Krejs, G.J., 2010, 
Malvezzi, M., et al., 2010, Sasako, M., et al., 2010, Shin, H.R., et al., 2010). Often seen in 
whites aged 60-80, the male to female ratio is 2:1, which rises up to 5:1 for proximal tumors 
(Krejs, G.J., 2010). The main risk factors related to the development of gastric cancer are 
Helicobacter pylori infection, dietary factors, tobacco use and obesity (Crew, K.D. Neugut, 
A.I., 2006, Krejs, G.J., 2010, Sasako, M., et al., 2010).  Having been the most important cancer-
related mortality in the United States in the 1930s for both sexes, its incidence and mortality 
rates have dramatically decreased over the years. For the year 2010, 21.000 new cases and 
11.000 deaths from stomach cancer are estimated in the United States (Jemal, A., et al., 2010).   
As the 4th most common cause of cancer-related deaths, gastric cancer incidence and 
mortality rates among the European countries also show significant variations  (Ferlay, J., et 
al., 2010, Krejs, G.J., 2010, Malvezzi, M., et al., 2010). The incidence of stomach cancer in men 
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is 8/100.000 and in women 3-4/100.000 in European Union (EU) countries. For Russia, these 
rates are 25 and 10 and for United Kingdom (UK) 5-6, and 2-3, respectively. Although 
decreased in major European countries, mortality rates still high in eastern and southern 
Europe with an estimated new cases of 150.000  and gastric cancer-related mortality 116.000 
for the year 2008 (Ferlay, J., et al., 2010).  
1.2 Surgical therapy 
There is no doubt that the only curative treatment option for gastric cancer is gastrectomy 
and regional lymph node dissection (Swan, R. Miner, T.J., 2006, Tanizawa, Y. Terashima, M., 
2010), although the most appropriate surgery and lymph node dissection are still 
controversial. The debate about surgical approach and extent of lymph node dissection 
continuing. In early gastric cancer, which is confined to the mucosa or submucosa, in Japan 
and Korea in particular, endoscopic mucosal dissection and endoscopic submucuosal 
resection is the usual management (Deprez, P.H., et al., 2010, Kim, J.J., et al., 2007).  
Although there are some discussions, subtotal gastrectomy and total gastrectomy is 
considered to be similar in terms of survival. The complex lymph nodes of stomach are 
classified by Japanese Gastric Cancer Association. According to this classification regional 
lymph nodes are divided to 3 groups according to the location of the primary tumor and 
lymph node dissection is separated into the D0, D1, D2 and D3. Perigastric lymph nodes 
have been recognized as D1 and the ones around the main branches of the celiac axis as D2 
(Japanese Gastric Cancer, A., 1998). The extent of lymph node dissection in gastric cancer 
surgery is one of the most controversial issues. D2 dissection was performed as a standard 
approach in Japan, Korea, and some Western countries. D1 dissection is done in many 
western countries.  One of the most well-known studies on this subject is the work of Dutch 
Gastric Cancer Group. In this study comparing D1 and D2 dissections, a 5-year overall 
survival and risk of relapse were similar, but perioperative mortality and complication rates 
were statistically significantly higher in D2 arm (Bonenkamp, J.J., et al., 1999). In a meta-
analysis, the benefit of the addition of paraaortic lymphadenectomy (PALD) to D2 
dissection was discussed and concluded that additional PALD didn’t show survival benefit 
and  was evaluated as less secure (Chen, X.Z., et al., 2010).   
D2 dissection and D2 with PALD were compared. While surgery related complication rate 
were similar between D2 and PALD groups, 5-year overall survival rates were 69.2% in D2 
arm and 70.3% in PALD arm [HR (hazard ratio) 1.03, CI (confidence interval) 0.77-1.37, p = 
0.85] (Sasako, M., et al., 2008).  
The 15 year results of Dutch study was recently published. The median follow-up was 15.2 
years.  D1 arm had higher locoregional relapse rate and higher gastric cancer related death 
rate (182, 48%) than D2 arm (123, 37%) (p =0.01). However, the overall survival rate of the 
D1 arm at 15 years  (21%, 85 of 380) and D2 arm (29%, 98 of 331) were similar (p = 0.34) 
(Songun, I., et al., 2010). You can see key elements of related trials in Table 1. 
In the meta-analysis of Yang and colleagues, it was shown that splenectomy didn’t have 
benefit and is not recommended as a routine practice (Yang, K., et al., 2009). However, 
current National Comprehensive Cancer Network (NCCN) guideline recommends D1 
(perigastric lymph nodes) and D2 (along  in with named vessels of celiac axis) dissection, 
with a goal of at least 15 lymph nodes removed at moderate to high volume centers (Ajani, 
J.A., 2011). Although D2 procedure has a higher postoperative mortality and morbidity, it is 
being applied as a standard approach with confidence at many large centers. 
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Study Intervention Patients 
(n) 
Postoperative 
Morbidity 
Postoperative 
Mortality 
5-Year 
Survival 
Dutch trial 
(1989-1993) 
D1 vs. D2 380/331 25.0%/43.0% 
(p<0,001) 
4.0%/10.0% 
(p<0,004) 
45.0%/47.0%, 
HR 1.00 
(95% CI, 0.82-
1.22) 
MRC trial 
(1987-1994) 
D1 vs. D2 200/200 28.0%/46.0% 
(p<0,001) 
6.5%/13.0% 
(p=0,04) 
35.0%/33.0%, 
HR 1.10 
(95% CI, 0.87-
1.39) 
Taiwanese 
trial 
D1 vs. D3 110/111 7.3%/17.1% 
(p<0,012) 
0%/0% 53.6%/59.5%, 
HR 0.49 
(95% CI, 0.32-
0.77) 
IGCSG 
trial 
(1999-2002) 
D1 vs. D2 76/86 10.5%/16.3% 
(p<0,29) 
0%/1.3% 
N.S 
Under 
analysis 
Table 1. Major randomized controlled trials comparing D1 with D2/D3 (Tanizawa, Y. 
Terashima, M., 2010) 
1.3 Prognostic factors and relapse pattern 
Based on 10 year results of the “German Gastric Cancer Study,” (Siewert, J.R., et al., 1998) 
they evaluated prognostic factors and they showed that lymph node ratio (ratio between 
positive and removed nodes; p<0.0001), residual tumor category (R0, Rl, R2; p <0.0001), pT-
category (pTl, pT2, pT3 and pT4; p<0.0001, postoperative complications (p<0.0001), distant 
metastases (MO, Ml; p=0.003) affected prognosis. In a prospective multicenter study; it was 
shown that nodal status, depth of invasion, limited or extended lymphadenectomy (D1 vs. 
D2-D3), tumor location (lower vs. upper) and age were independent predictors of 
recurrence (Marrelli, D., et al., 2005). It was also shown that T (T2 vs. T3, risk ratio 3.55, 95% 
CI 1.98-6.44 and p: 0.001) and histological type (intestinal vs. diffuse/mixed, risk ratio 2.11, 
95% CI 1.25-2.95 and p: 0.021) were independent prognostics indicator in node negative 
gastric cancer patients (Baiocchi, G.L., et al., 2010).  Depth of tumor invasion and nodal 
involvement are considered the most important prognostic factors (Marrelli, D., et al., 2005). 
Although in many cases surgical treatment is the primary treatment, usually locoregional, 
hematogenous, and peritoneal recurrences are seen and in patients with developing relapse 
an effective treatment option isn’t available (Marrelli, D., et al., 2005). Studies have 
demonstrated that at least half of all patients who undergo curative resection will have 
locoregional, peritoneal or distant recurrence (Table 2) (Baiocchi, G.L., et al., 2010, 
Bonenkamp, J.J., et al., 1999, Buzzoni, R., et al., 2006, D'Angelica, M., et al., 2004, de 
Manzoni, G., et al., 2003, Kattan, M.W., et al., 2003, Marrelli, D., et al., 2005, Otsuji, E., et al., 
2004, Wang, S.Y., et al., 2009), meaning that surgery alone was unable to eradicate all 
locoregional disease in the majority of patients. 
Therefore in addition to surgical resection, the need for systemic and local therapies are 
apparent. Various preoperative, perioperative and postoperative regimens, chemotherapy 
(CT), radiotherapy (RT) or combining therapy, have been designed to eradicate microscopic 
disease.  
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Reference 
Types of relapse (%) 
Locoregional Peritoneal Distant Multiple-sites 
(Marrelli, D., et al., 2005) 23.7 16.2 17.2 7.8 
(Buzzoni, R., et al., 2006) 15.8 N.S 34.5 N.S 
(Otsuji, E., et al., 2004) 16.0 54.0 31.0 N.S 
(Wang, S.Y., et al., 2009) 9.5 23.3 20.6 46.6 
(de Manzoni, G., et al., 2003) 32.7 18.1 40 9 
(D'Angelica, M., et al., 2004) 25.9 13.6 28.1 32.5 
(Sakuramoto, S., et al., 2007)* 11.5 15.8 11.3 N.S. 
(Macdonald, J.S., et al., 2001)* 29.0 72.0 18.0 N.S. 
N.S.: not specified *Site of first relapse,  
Table 2. Type of relapse after curative resection  
The majority of patients with gastric cancer are diagnosed at advanced stages. Even in 
patients are diagnosed at an early stage, 5-year survival rate of patients undergoing surgery 
alone is low. While the 5 year survival rates are about 70.0% in patients with stage IA, it is 
20.0% in patients  with stage III  (Edge, S. Byrd, D., 2010). Therefore, it is clear that 
treatments in addition to surgery for gastric cancer are needed. For this reason, a lot of 
studies in terms of neoadjuvant, perioperative, or adjuvant RT, CT or combined approaches 
have been tried. 
1.4 Possible therapeutic strategies to improve outcome of surgical therapy 
CT, RT or combinations of the 2 can therotically be applied before (neoadjuvant) or after 
(adjuvant) the curative surgery. Being applied earlier in time, neoadjuvant therapy is 
expected to down stage the disease and increase the rate of curative resection and eradicate 
possible micrometastases, which are undetectable at the beginning of the treatment. In 
addition, pre-surgical patients usually have better performance status and can be expected 
to tolerate  treatments better. However on the other hand, patients with initially resectable 
disease could loose their chance of curative surgery and postsurgical mortality may be 
increased. One other pitfall of neoadjuvant therapy is imperfectness of clinical staging. 
There is a possibility to give unnecessay oncological treatments to patients with very early 
stages of cancer who would not have otherwise receive based on pathological staging . Prior 
to surgery, yet the normal anatomy and blood flow, target volumes of RT could be more 
easily detected.  However, more patients have metastatic disease at surgery than patients 
undergoing preoperative reviews. Two randomized important studies on this subject were 
the Magic and Holland trials (Cunningham, D., et al., 2006, Hartgrink, H.H., et al., 2004). 
In the adjuvant setting, pathological staging is known. There is no danger of giving 
unnecessary treatment. However, patients can tolerate adjuvant therapies less and CT or RT 
could not be applied at effective doses. In addition, blood flow to the gastric bed may be 
decreased after surgery which leads to tissue hypoxia. Hypoxic tumor cells do not 
proliferate to the extend at which non-hypoxic tumors do. Since many chemotherapeutics 
and RT are more effective on hypoxic cells, adjuvant therapeutic strategies may be less 
effective than expected. 
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2. Neoadjuvant trials 
2.1 Neoadjuvant radiotherapy 
Neoadjuvant randomized clinical trial evaluating the efficacy of RT alone is limited. Zhang 
et al. randomized 370 patients with gastric adenocarcinoma of cardia to surgery alone or RT 
and surgery group. In the RT arm patients, underwent surgery 2-4 weeks after 40 Gy.  The 
rate of tumor resectability and ratio of T2 tumor were more in RT arm with 11.0% decrease 
of T4 tumors. Five- and 10-year survival rates for RT plus surgery and surgery alone groups 
were 30.1%, 19.7% and 20.2%, 13.3%; respectively and these differences were statistically 
significant. No significant difference was observed between 2 group in term of surgical 
complication rates (Zhang, Z.X., et al., 1998). 
In another study preoperative RT in resectable gastric cancer, there were 51 patients in both 
RT plus surgery and surgery alone arms and the total doses of RT was 20 Gy and was given 
in 5 fractions. Although,  statistically insignificant, 5- and 10-year survival rates were 39.0%, 
32.0% and 30.0%, 18.0% for the preoperative RT and surgery alone groups, respectively.  
Although concentrated preoperative RT was safe, wasn’t enough to provide survival 
advantage (Skoropad, V., et al., 2002).  
Fiorica et al. were evaluated 9 randomized trials (with these two above study, 4 neoadjuvant 
and 5 adjuvant trials). In this meta-analysis; 3-year (HR 0.57, CI 95% 0.43 – 0.76; p= 0.0001) 
and 5-year (HR 0.62 CI 95% 0.46 – 0.84; p= 0.002) survival advantage were observed with 
preoperative RT. Although there was increasing trend in postoperative mortality for 
preoperative RT group, these difference wasn’t statistically significant  (HR 0.61 CI 95% 0.24 
– 1.57; p= 0.31) (Fiorica, F., et al., 2007).   
2.2 Neoadjuvant chemo(-radio)therapy 
The CT regimens have been used in patients with metastatic disease has led the way for 
regimens which could be used as neoadjuvant CT. The first randomized controlled 
neoadjuvant CT trial was Dutch randomized FAMTX (5-Fluorouracil, doxorubicin and 
Methotrexate)  trial. There were 56 patients and FAMTX regimen was used. The ratio of 
resectability was similar and at median follow-up of 83 months the median survival is 18 
months for FAMTX group vs. 30 months in surgery alone group (p=0.17). This trial could 
not show a beneficial effect of pre-operative FAMTX, even  preoperative CT tends to have 
negative effect (Hartgrink, H.H., et al., 2004). However, it is clear that FAMTX regimen isn’t 
an effective treatment option for today. In addition, fewer patients have been taken than 
planned in this study,  25.0% of patients did not receive the planned treatment because of 
toxicity associated with CT.   
The MAGIC trial is one of the most important neoadjuvant CT studies. In this study ECF 
(epirubicin, cisplatin, and infusional 5-fluorouracil) regimen, which is more effective than 
FAMTX regimen in patients with metastatic disease, was used. ECF CT regimen was 
compared surgery alone. Patients with resectable adenocarcinoma of the stomach, 
esophagogastric junction, or lower esophagus were ranomized to either perioperative CT 
and surgery (250 patients) or surgery alone (253 patients). CT consisted of 3 preoperative 
and 3 postoperative cycles of intravenous epirubicin (50 mg per square meter of body-
surface area) and cisplatin (60 mg per square meter) on day 1, and a continuous intravenous 
infusion of fluorouracil (200 mg per square meter per day) for 21 days (Cunningham, D., et 
al., 2006). Of patients, 90.7% completed preoperative CT, but only 103 of 208 (49.5%) who 
completed preoperative CT and surgery also completed postoperative treatment. The 
curative resection rates were similar; 69.3% in the perioperative CT group and 66.4% in the 
surgery group. There was a greater proportion of stage T1 and T2 tumors and less advanced 
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nodal disease in the perioperative-CT group. The perioperative-CT group had a higher 
likelihood of overall survival (hazard ratio for death, 0.75; 95% CI, 0.60 to 0.93; p= 0.009; 5-
year survival rate, 36% vs. 23%) and of progression-free survival (hazard ratio for 
progression, 0.66; 95% CI, 0.53 to 0.81; p<0.001). 
3.1 Adjuvant chemotherapy 
Numerous clinical trials concerning adjuvant CT for gastric cancer have been conducted 
with different CT regimens.  The results of adjuvant CT trials are conflicting as well, 
majority being negative with disparities between asian and western ones. Geographic  
 
 
Author 
Patient 
(n) 
Neoadjuvant 
approach 
PR 
% 
pCR
% 
R0 
resection
% 
OS 
(months)
OS for R0 
resection 
patients 
(months) 
(Menges, M., 
et al., 2003) 
25 
3 or 4 cycles of C,
5-FU, FA
73.0 0 65.0 15.5 23.0 
(Schuhmach
er, C.P., et 
al., 2001) 
42 
3 or 4 cycles of Et-
D-C 
N.S. 0 73.8 19.1 28.4* 
(Ajani, J.A., 
et al., 2006) 
43 
2 cycles of 
induction C, 5-FU, 
FA followed 
concurrent RT and 
weekly infusional 
5-FU
N.S. 26.0 77.0 23.2 N.R. 
(Hartgrink, 
H.H., et al., 
2004) 
59 (29 
vs.30) 
4 cycles of 
FAMTX vs. 
surgery alone
32.0# 
62.0 vs. 
63.0 
18.2 
vs.30.3 
30.0 vs. 66.0 
(Biffi, R., et 
al., 2010) 
69 (34 
vs. 35) 
4 cycles of T-C-
5FU 
Arm A 
(preoperative) 
Arm B 
(postoperative)
55.0 11.7
85.0 vs. 
91.0 
N.S. N.S. 
(Schuhmach
er, C., et al., 
2010) 
144 (72 
vs.72) 
2 cycles of C, 5-
FU, FA  vs. 
surgery alone
5.8 30.4
81.9* 
vs.66.7 
64.6 vs. 
52.5 
N.S. 
(Cunningha
m, D., et al., 
2006) 
503 (250 
vs. 253)
3 preoperative 
and 3 
postoperative 
cycles of E, C, 5-
FU vs. surgery 
alone
N.S. N.S.
69.3 vs. 
66.4 
36.0 vs. 
23.0* 
(5 year 
survival 
rate) 
N.S. 
*Statistically significant, C:cisplatin, FU:fluorouracil, FA: folinic asid, RT: radiotherapy, D: doxorubicin, 
Et:etoposide, N.S.: not specified, N.R.:not reached, MTX: methoterxate, #PR or pCR, PR: partial 
response, pCR: pathologic complete response, E:epirubicin, T:docetaxel, FAMTX: fluorouracil, 
doxorubicin, methoterxate  
Table 3. Major randomized controlled Neoadjuvant trials 
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variation, small sample sized studies, differences in the surgical techniques account for these 
conflicting results. However, this does not mean that adjuvant chemotherapies are useless. 
Compared to current counterparts, CT regimens used in those old studies are relatively-
weaker regimes. Many studies are undepowered. Many meta-analyses investigating the role 
of adjuvant CT for gastric cancer have been performed to overcome such inconsistencies. 
 
Author  Year No. of studies Patients OR/HR 
(95%CI) 
(Hermans, J., et al., 
1993) 
1993 11 2096 0.88 (0.78-1.08) 
(Earle, C.C. Maroun, 
J.A., 1999) 
1999 13 1990 0.80 (0,66-0,97)* 
 (Mari, E., et al., 2000) 2000 21 3658 0,82 (0,75-0,89)* 
(Liu, T.S., et al., 2008) 2008 23 4919 0,85 (0,80-0,90)* 
(Paoletti, X., et al., 
2010) 
2010 17 3838 0,82 (0,76-0,90)* 
OR: Odds ratio, * statistically significant values for survival 
Table 4. Meta-analyses of adjuvant chemotherapy in gastric cancer 
A meta-analysis was conducted on 13 randomized trials of adjuvant CT in gastric cancer 
concluded that adjuvant CT might produce a small survival benefit with a borderline 
statistical significance (Earle, C.C. Maroun, J.A., 1999). The trials in this meta-analysis were 
all performed in Western countries. Marie et al reviewed 20 clinical trials of adjuvant CT 
compared with surgery alone published between 1983 and 1999. Reviewers suggested that 
CT reduced the risk of death by 18% (HR 0.82, 95% CI: 0.75-0.89) and addition of 
anthracyclines to 5-FU did not show a statistically significant improvement when compared 
with other regimens (Mari, E., et al., 2000). The meta-analysis published in 2008 by Liu et al. 
based on 23 randomized clinical trial included 4919 patients (2441 in the adjuvant CT arm, 
2478 in the observation arm). The study showed relative risk on death of 0.85 (95%CI: 0.80-
0.90) which favored the survival role of adjuvant CT.  The authors of this meta-analysis 
concluded that NNT (number needed to treat) was 14, indicating that 14 patients would 
need to receive adjuvant therapy to prevent one death (Liu, T.S., et al., 2008). However, 
meta-analyses mentioned above were restricted since they were based on the review of the 
literature rather than original individual patient data. Recently, an individual patient level 
meta-analysis of randomized control trials was published by GASTRIC (Global 
Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group.  The 
meta-analysis based on 17 trials (including 3838 patients) comparing adjuvant CT with 
surgery alone for resectable gastric carcinoma. In the study four groups of CT regimens 
were defined: 1) monochemotherapy agents 2) fluorouracil, mitomycin C and other 
therapies without anthracyclines 3) fluorouracil, mitomycin C, and anthracyclines 4) other 
polychemotherapy regimens.  The study revealed statistically significant benefit associated 
with adjuvant CT both for overall survival (OS) (HR, 0.82; 95% CI, 0.76-0.90) and disease-
free survival (DFS) (HR, 0.82; 95% CI, 0.75-0.90, P<.001, for both). There was no significant 
difference between 4 CT regimens in terms of OS and DFS. The reviewers suggested that, 
adjuvant fluorouracil –based CT, even as monotherapy, had improved overall survival after 
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curative resection of gastric cancer (Paoletti, X., et al., 2010). Also in the meta-analyses of 
Sun et al. the pooled HR for overall survival was 0.78 (95 per cent confidence interval 0.71 to 
0.85) in favor of CT (Sun, P., et al., 2009). 
S-1 is an orally active combination of tegafur, gimercil and oteracil that has an appropriate 
bio-availability for using after gastrectomy. The Japanese randomized phase 3 trial assessed 
the efficacy of S-1 monotherapy as adjuvant CT in resected gastric cancer. In the study 
conducted by Sakuramoto et al. 1059 patients with stage 2-3 gastric cancer randomized to 
surgery only or adjuvant therapy with S-1 after extended (D2) gastrectomy. In the interim 
analysis after median follow-up of 2 years both overall survival and relapse-free survival 
differed between two groups favoring adjuvant CT arm, so the data and safety monitoring 
committee recommended early discontinuation of the trial. The study disclosed that the 
hazard ratio for death in the S1 group, as compared to surgery only group was 0.68 (95% CI, 
0.52-0.87, P=0.003) and 3-year overall survival of 80.1% vs. 70.1% respectively. The authors 
suggested that S-1 was potent adjuvant CT for East Asian patients who underwent D2 
dissection for locally advanced gastric cancer (Sakuramoto, S., et al., 2007). After this trial 
adjuvant CT without radiation therapy has been the standard in Japan.  
In conclusion, adjuvant CT may be considered in patients with locally advanced gastric 
cancer after curative surgery who had not received neoadjuvant treatment and not 
candidate for chemoradition therapy. 
3.2 Adjuvant radiotherapy 
One randomized clinical trial evaluated the role of adjuvant RT after curative resection in 
gastric cancer (without concurrent CT). According to the trial performed by British Stomach 
Cancer Group 436 patients with resected gastric cancer were stratified to no adjuvant 
treatment or adjuvant RT or adjuvant CT with adriamycin, 5-FU and mitomycin C. The five 
year survival rates were as follows: for surgery alone 20%, for surgery plus RT 12.0%, for 
surgery plus CT 19.0%. No advantage in terms of survival in either adjuvant arm was 
observed, but RT offered an advantage in reducing local recurrence as compared to surgery 
only group (local recurrence rates were 27.0% versus 10.0% favoring surgery plus RT 
(Hallissey, M.T., et al., 1994). 
3.3 Adjuvant chemoradiotherapy 
Gastric cancer can recur loco-regionally, or systemically. The review from Memorial Sloan-
Kettering Cancer (MSKCC) demonstrated patterns of relapse of 1172 patients who 
underwent potentially curative surgery from July 1985 through June 2000 (D'Angelica, M., 
et al., 2004). Among 496 patients who had a recurrence, whole data on recurrence was 
obtained in 367 patients.  Loco-regional sites were a component of relapse in 54.0% of 
patients including the anastomosis, lymph nodes and the gastric bed. Distant sites and 
peritoneal relapse were documented in 51.0% and 29.0% of patients, respectively. Since 
adjuvant RT alone did not appear to confer advantage in terms of survival, RT combined 
with CT was evaluated in randomized clinical trials. The rationale to use CRT in the 
adjuvant setting in gastric cancer is not only to control loco-regional recurrence but also 
distant metastases. First, when used concurrently with RT chemotherapeutic agents may act 
as a radio-sensitizer. Second, CT may improve systemic control by eliminating microscopic 
distant metastasis. Various mechanisms are responsible for the interaction between CT and 
RT. Ionizing radiation induces DNA base damage, alkali-labile sites, single-strand breaks, 
and double strand breaks. Double strand breaks are the most important damage among 
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them and causes tumor-kill whether remains unrepaired. Chemotherapeutic agents that 
inhibit DNA repair, including fluorouracil, cisplatin, irinotecan, can improve radiation 
cytotoxicity synergistically. CT can also act by restraining post-radiation damage repair. The 
phase of the cell cycle is another determinant of radio-sensitivity. While cells in G2-M phase 
are most radiosensitive, cells in the S phase of the cell cycle are the most radio-resistant 
(Terasima, T. Tolmach, L.J., 1961). CT and RT also produce synergistic effect by targeting 
different phases of the cell cycle when used concurrently. Moreover, drugs such as taxanes 
has the ability to block the cell cycle at the G2-M phase so that enhances the radiation effect 
(Tishler, R.B., et al., 1992).  
Several randomized trials assessed the effectiveness of chemo-radiation after curative 
surgery. Dent et al. performed randomized trial including 142 patients with all stages of 
gastric carcinoma. The patients in Division I (T1-3, N1-2, and M0) were assigned to control 
and RT plus 5-FU group. Division II (T4, M1) was randomized into three groups; a control 
group, RT plus 5-FU, thiotepa for six months. After 4.5 year’s follow-up the control and 
treatment groups did not differ with respect to survival rate in neither Division I nor 
Division II (Dent, D.M., et al., 1979). In the randomized trial conducted by Bleiberg and 
colleagues, 115 patients who underwent curative and palliative surgery were stratified into 
four treatment groups. Patients received RT alone or in combination with short-term and/or 
long term 5-FU infusion. Statistically differences were determined in terms of overall 
survival but the difference in survival disappeared when comparisons adjusted for 
prognostic factors (Bleiberg, H., et al., 1989). In the study by Moertel and co-workers 62 
patients with resectable but poor prognosis gastric carcinoma were randomized to surgery 
versus surgery plus adjuvant treatment with 5-FU plus radiation. Although both five-year 
survival rates and local-regional recurrence favored treatment arm results did not reach 
statistical significance (Moertel, C.G., et al., 1984). 
The largest trial evaluating the use of postoperative chemoradiation was U.S. Intergroup 
0116 trial (Macdonald, J.S., et al., 2001). In this study 556 patients with curatively resected 
gastric or gastroesophageal junction adenocarcinoma (stage Ib through IV M0) were 
randomized to surgery alone or adjuvant combined chemoradiotherapy (CRT). The 
adjuvant treatment consisted of one course of 5-FU 425 mg/m2/d and leucovorin 20 
mg/m2/d, daily for five days, followed one month later by 45 Gy of radiation during 5 
weeks with 5-FU 425 mg/m2/d and leucovorin 20 mg/m2/d on days 1 through 4 and last 3 
days of radiation. One month after completion of RT 2 more 5-day cycles of CT (5-FU 425 
mg/m2/d plus leucovorin 20 mg/m2/d) were administered. After a median follow-up of 5 
years, the median duration of survival was 36 and 27 months in the CRT and surgery-only 
groups, respectively. The 3-year survival rates were 50% versus 41% favoring adjuvant 
treatment. The 3-year rates of relapse free survival increased from 31.0% to 48.0% in the CRT 
group. Improvements both in overall and relapse free survival were statistically significant. 
Grades 3 and 4 toxic effects (mostly, hematologic and gastrointestinal) occurred in 41.0% 
and 32.0% of chemo-RT groups, respectively. Three patients (%1) died as a result of toxic 
effect of the treatment. The extent of the surgical resection was an important issue in the 
study protocol. Although, D2 dissection was recommended, only 10.0% of patients 
underwent a D2 dissection, 54.0% of the patients underwent D0 dissection (in which all of 
the N1 nodes were not resected). When patients relapse patterns were examined, local-
regional recurrence was higher in the surgery only group, despite the higher distant 
metastasis rates detected in the CRT group (statistical assessment of the relapse sites were 
not included in the study). The study demonstrated that the benefit of CRT in the adjuvant 
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setting was mainly apparent by reducing loco-regional recurrence. At the end of the study 
Macdonald et al. suggested that, postoperative CRT should be considered for all patients at 
high risk for recurrence of adenocarcinoma of the stomach or gastro-esophageal junction 
who undergone curative resection. 
4. Intra-peritoneal chemotherapy      
Peritoneal spread of tumor cells is frequently seen in the course of gastric carcinoma. The 
expected median survival time is approximately 3 to 6 months when peritoneal 
carcinomatosis and ascites become evident (Sakata, Y., et al., 1998). The rationale to use 
peritoneal route to prevent and/or treat the peritoneal spread is to deliver higher 
concentrations of CT within peritoneal cavity without marked systemic toxicity. Several 
randomized trials assessed the role of intra-peritoneal CT with different aspects regarding 
the timing of drug administration, the type of chemotherapeutic agents and the impact of 
hyperthermia. At least two meta-analyses of randomized clinical trials on adjuvant intra-
peritoneal CT for curatively resected gastric cancer showed clinical benefit of this treatment. 
The meta-analysis by Xu and colleagues included eleven trials involving 1161 cases (Xu, 
D.Z., et al., 2004). All included trials were randomized, controlled trials that compared 
surgery plus intra-peritoneal CT with or without activated carbon particles with surgery 
alone. No other adjuvant treatment including oral or parenteral CT, RT or chemo-
immunotherapy was used in the adjuvant group. In the study 609 patients were assigned to 
the treatment group and 552 to the control group. Most of the studies used mitomycin C 
with or without carbon particles as a chemotherapeutic agent. The pooled odds ratio was 
0.51 with a 95% confidence interval (0.40-0.65). Moreover, in the subgroup analysis trials 
that used intra-peritoneal hyperthermic chemoperfusion or CT with activated carbon 
particles was more effective than the trials without hyperthermia and carbon particles. The 
other meta-analysis performed by Yan and coworkers also involved 13 randomized control 
trials that compared surgery plus intra-peritoneal CT to surgery alone (Yan, T.D., et al., 
2007). The trials included patients with locally advanced gastric cancer without distant 
metastasis. In the study intra-peritoneal chemotherapies grouped in five categories 
according to the timing of the procedure and whether hyperthermia was used. The 1st group 
was composed of trials assessing the role of hyperthermic intra-operative intra-peritoneal 
CT (HIIC). The 2nd group involved trials investigating normothermic intra-operative intra-
peritoneal CT (NIIC). The 3rd group was composed of trials exploring the efficiency of early 
postoperative intra-peritoneal CT (EPIC). The 4th group included combined forms and the 
5th group included the trials of delayed postoperative intra-peritoneal CT (DPIC). The study 
showed significant survival benefit in favor of HIIC (Hamazoe, R., et al., 1994) (HR:0.60; 
95% CI;0.43-0.83) and HIIC combined with EPIC (Gao Z, J.Z., Zhou F, 2002, Wei, G., et al., 
2005) (HR:0.45;95%CI:0.29-0.68). The improved survival provided by NIIC did not reach 
statistical significance (Rosen, H.R., et al., 1998, Takahashi, T., et al., 1995, Yonemura, Y., et 
al., 2001) (HR:0.67;95% CI:044-1.01; p=0.06), no benefit was found either with EPIC 
(HR:0.64;95% CI:037-1.10) or DPIC (HR:0.89;95% CI:0.51-1.55). The meta-analysis did not 
show significant difference in perioperative mortality between the 2 arms. The incidence of 
intra-abdominal abscess was significantly higher among patients in the intra-peritoneal CT 
arm. Though none of the individual trial showed increased incidence in terms of 
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neutropenia the meta-analysis found intra-peritoneal chemotherapy associated with 
increased risk of neutropenia. The authors of the meta-analysis concluded that HIIC with or 
without EPIC after resection of advanced gastric cancer was associated with improved 
overall survival at the expense of  increased risk of intra-abdominal abscess and 
neutropenia. 
5. Current standard of care in the world 
Surgical resection with lymph node dissection is the primary treatment of early gastric 
cancer. Total gastrectomy is preferred for tumors arising from proximal stomach or tumors 
infiltrating stomach diffusely. For distal gastric cancers subtotal gastrectomy is procedure of 
choice due to fewer complications, lower morbidity and similar survival compared with 
total gastrectomy (Bozzetti, F., et al., 1999). Endoscopic mucosal resection is the standard 
treatment in Japan for early gastric cancer limited to mucosa without lymph node 
involvement  (Soetikno, R., et al., 2005). 
The extent of lymph node dissection still remains to be a matter of debate.  Although 
gastrectomy with D2 lymphadenectomy is the standard treatment in Japan, in Western 
studies extensive lymphadenectomy have not provided survival benefit when compared 
with D1 lymph node dissection (Bonenkamp, J.J., et al., 1999). D2 dissection is more and 
more adopted in western societies. 
 In United Kingdom and most of the parts of Europe perioperative CT with ECF regimen 
became the standard of care, based on the results of the MAGIC trial. This approach is also 
recommended with level 1 evidence in United States (U.S.) for patients with T2 or higher 
tumors.  
The results of INT-0116 trial changed standard of care in United States from observation to 
chemo-radiation after curative resection of gastric cancer without evidence of metastasis. 
Patients with T3, T4 or node positive tumors are recommended to be treated with RT (45-50 
Gy) concurrent with 5-FU plus 5-FU (with leucovorin) after curative resection in U.S., 
although this approach has not been accepted in most of Europe and Japan. 
In Japanese population adjuvant CT with S-1 was detected to improve survival after gastric 
resection with D2 lymph-node dissection in stage II-III gastric cancer. Though it seems to be 
feasible adjuvant treatment option in East Asian patients, there is not enough data to 
recommend this approach in Western population. 
6. Future directions   
Despite advances both in adjuvant and metastatic setting, overall survival in gastric cancer 
remains to be poor. New agents and new schedules which have been proved to be effective 
are being integrated into trials of neoadjuvant or adjuvant trials. Emerging data from clinical 
trials evaluating combination chemotherapies and new molecular targeted therapies has 
shown clinical benefit especially in metastatic disease. The efficacy of these novel therapies 
should be confirmed in well designed prospective randomized clinical trials.  
Newer chemotherapeutic agents, namely taxanes, oral fluoropyrimidines (UFT, S1, 
capecitabine) and irinotecan have widely searched in advanced stages of gastric cancer. 
Naturally, it is expected that the most effective and tolerable chemotherapeutic strategies in 
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the metastatic setting should be evaluated in earlier stages. In the V325 trial by Van Cutsem 
et al. the combination of docetaxel, cisplatin and 5-FU (DCF), was significantly superior than 
cisplatin plus 5-FU (CF) in terms of OS, time to tumor progression and response rate (Van 
Cutsem, E., et al., 2006). In the phase II randomized trial (NEOTAX) DCF combination CT 
will be evaluated as a neoadjuvant therapy in locally advanced gastric adenocarcinoma 
(Clinicaltrials.gov number is NCT00343239). The objective of this study is to determine the 
impact of DCF combination CT on R0 resection rate in gastric cancer. Patient recruitment is 
over and the first results are expected in January 2012. 
In the large CRITICS trial, the question of whether adjuvant CRT with weekly cisplatin  and 
capecitabine after 3 cycles of neoadjuvant ECC (epirubicin, cisplatin and capecitabine) and 
surgery in comparison with 3 more cycles of the neoadjuvant schedule (clinicaltrials.gov no: 
NCT00407186). Nearly 800 patients are expected to be recruited and the first results are 
awaited in 2013. 
The rationale to combine targeted therapies with CT is to improve the efficacy with 
acceptable toxicity. Epidermal growth factor receptor 2 (also known as HER-2) has become 
important target in gastric cancer. Trastuzumab, a fully humanized monoclonal antibody 
against HER-2, was recently evaluated in metastatic gastric cancer. In randomized phase 3 
ToGA trial patients were randomly assigned to receive trastuzumab plus CT (capecitabine 
plus cisplatin or fluorouracil plus cisplatin) or CT alone. The study revealed that median 
overall survival was 13.8 months in those assigned to trastuzumab plus CT as compared 
with 11.1 months in those received CT alone (HR: 0.74; 95% CI:0.60-0.91; P=0.046). The 
authors suggested that trastuzumab plus CT substantially improved OS in patients with 
high expression of HER-2 protein (immunohistochemistry 2+ and FISH + or 
immunohistochemistry 3+) compared with patients with low expression of HER-2 
(immunohistochemistry 0 or 1+ and FISH+). It was also reported that combining 
trastuzumab with CT did not cause additional toxic effect (Bang, Y.J., et al., 2010). It is 
currently not known whether the benefit achieved in metastatic gastric cancer will be 
translated to adjuvant setting. It was also shown that replacing cisplatin with oxaliplatin and 
fluorouracil with capecitabine is not inferior than the classical ECF (epirubicin, cisplatin, 
fluorouracil)(Okines, A.F., et al., 2009).  A study of capecitabine in combination with 
trastuzumab and oxaliplatin in patients with resectable gastric cancer, namely TOXAG 
(Trastuzumab, Oxaliplatin, and Xeloda for Adjuvant Gastric Cancer) was recently designed 
to evaluate the impact of trastuzumab in adjuvant and adjuvant strategy. 
Bevacizumab, recombinant humanized monoclonal antibody that targets vascular 
endothelial growth factor, was recently studied in combination with irinotecan and cisplatin 
in patients with metastatic gastric adenocarcinoma in a phase II multicenter study (Shah, 
M.A., et al., 2006). The study revealed that, time to disease progression improved by 75% in 
compared to historical controls. Rates of rare but important complications of bevacizumab, 
namely gastrointestinal perforation and hemorrhage, was also found similar to rates of 
several recent large advanced phase studies. The authors of this study concluded that 
bevacizumab could be added to CT safely and was active in the treatment of advanced 
gastric adenocarcinoma. A randomized phase III trial will assess the safety and efficacy of 
neoadjuvant and adjuvant CT including epirubicin, cisplatin and capecitabine with or 
without bevacizumab in patients with untreated resectable gastric or gastroesophageal 
junction cancer (MAGIC-B Study) (clinicaltrials.gov no: NCT00407186). Planning to have 
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1100 patients, the results of this study may clarify the role of bevacizumab in 
adjuvant/neoadjuvant setting. 
There are also adjuvant studies exploring the role of S-1, a newer oral fluoropyrimidine 
analog. 
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